Aquestive Therapeutics (AQST) Receivables (2017 - 2026)

Aquestive Therapeutics' Receivables history runs 10 years deep, the most recent figure standing at $8.5 million for Q1 2026.

• In Q1 2026, Receivables fell 24.1% year-over-year to $8.5 million; the TTM figure through Mar 2026 stood at $8.5 million (down 24.1% YoY), while the FY2025 annual figure was $27.5 million, up 180.26% from the prior year.
• Receivables was $8.5 million for Q1 2026 at Aquestive Therapeutics, down from $27.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $27.5 million in Q4 2025 to a low of $6.6 million in Q2 2024.
• Historically, Receivables has averaged $12.7 million across 5 years, with a median of $11.1 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Receivables slumped 56.35% in 2022, then surged 180.26% in 2025.
• A 5-year view of Receivables shows it stood at $6.8 million in 2022, then rose by 24.0% to $8.5 million in 2023, then climbed by 15.7% to $9.8 million in 2024, then soared by 180.26% to $27.5 million in 2025, then tumbled by 69.21% to $8.5 million in 2026.
• The last three Receivables figures came in at $8.5 million (Q1 2026), $27.5 million (Q4 2025), and $14.1 million (Q3 2025), per Business Quant data.